Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil

被引：10

作者：

Arenas, J

Fernández-Moreno, MA

Molina, JA

Fernández, V

del Hoyo, P

Campos, Y

Calvo, P

Martín, MA

García, A

Moreno, T

Martínez-Salio, A

Börnstein, B

Bermejo, F

Cabello, A

Garesse, R

机构：

[1] Univ Madrid, Hosp 12 Octubre, Ctr Invest, Madrid 28041, Spain

[2] Univ Madrid, Hosp 12 Octubre, Serv Neurol, Madrid 28041, Spain

[3] Univ Madrid, Hosp 12 Octubre, Serv Anat Patol, Madrid 28041, Spain

[4] UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain

来源：

NEUROLOGY | 2003年 / 60卷 / 01期

关键词：

D O I：

10.1212/01.WNL.0000042050.85041.FB

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors describe a patient who presented with myoglobinuria after starting cerivastatin-gemfibrozil therapy. Muscle histochemistry revealed ragged-red fibers and cytochrome c oxidase negative (COX) fibers, and biochemistry showed a defect of COX activity. Immunoblot analysis showed a 60% reduction of COX I and COX II polypeptides. Cerivastatin myotoxicity might be related to a depletion of essential metabolites needed to anchor COX subunit I to mitochondrial membrane.

引用

页码：124 / 126

页数：3

共 9 条

[1]

DiMauro S, 2000, BRAIN PATHOL, V10, P431

[2] HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture [J].